Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Session VI: Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials

New response criteria for immunotherapy to capture response patterns in advanced melanoma patients treated with ipilimumab: Results from two phase II trials

Jedd Wolchok
Jedd Wolchok
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Ipilimumab is a monoclonal antibody directed against cytotoxic T lymphocyte antigen-4 (CTLA-4). Previous reports have noted that modified World Health Organization (mWHO) criteria may not fully capture ipilimumab clinical benefit. Here we present response and survival data, analyzed by mWHO or proposed novel efficacy endpoints, from 227 previously-treated patients with advanced melanoma enrolled in 2 Phase II trials. Patients received 10 mg/kg ipilimumab every 3 weeks (Q3W) X 4; eligible patients received 10 mg/kg ipilimumab maintenance therapy Q12W starting at Week 24. Response was assessed by Independent Review Committee (IRC) using mWHO criteria (complete response [CR], partial response [PR], stable disease [SD], and progressive disease [PD]) starting from Week 12. Follow-up was obtained in some patients after PD if they did not receive other therapies. Best overall response rate (BORR, CR+PR), disease control rate (DCR, CR+PR+SD), overall survival (OS) and 1-year survival were determined. Novel response endpoints, termed immune-related response criteria (irRC), were designed (using mWHO as a foundation) to systematically capture patterns of clinical activity and characterize changes in total measurable tumor burden over time (index + new lesions, when present) before and after mWHO PD. Survival was analyzed by DCR according to mWHO or novel efficacy endpoints. Overall, 4 response patterns were observed: 2 conventional (response in baseline lesions and 'stable disease', often with slow, steady decline in total tumor burden) and 2 novel (response after initial increase in total tumor burden and response in index and new lesions after the appearance of new lesions). The mWHO BORR was 7.5% (17/227). The median OS was 10.7 months (95% CI 7.8, --) and 1-year survival rate was 48.6% (95% CI 40.6, 54.9) with 0.2-18.7 months of follow-up. The median OS for patients with mWHO CR/PR/SD and for those with responses captured by the novel efficacy endpoints (mWHO PD followed by tumor shrinkage) were comparable and have not yet been reached. These data suggest that mWHO-classified PD may not always be a surrogate for drug failure in ipilimumab-treated melanoma patients. Novel response criteria such as irRC, which track tumor burden (including new lesions, when present) before and after mWHO PD, may better characterize the clinical activity of ipilimumab and other immunotherapies. Survival follow-up is ongoing.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Jedd Wolchok
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 2)
January 2008
Volume 8, Issue Suppl 2
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
New response criteria for immunotherapy to capture response patterns in advanced melanoma patients treated with ipilimumab: Results from two phase II trials
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New response criteria for immunotherapy to capture response patterns in advanced melanoma patients treated with ipilimumab: Results from two phase II trials
Jedd Wolchok
Cancer Immun January 1 2008 (8) (Suppl 2) 25;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
New response criteria for immunotherapy to capture response patterns in advanced melanoma patients treated with ipilimumab: Results from two phase II trials
Jedd Wolchok
Cancer Immun January 1 2008 (8) (Suppl 2) 25;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Identification of antibody responses induced in patients with biochemically recurrent and castration-resistant prostate cancer receiving GVAX immunotherapy for prostate cancer
  • Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment
  • Harmonized T cell monitoring assays as biomarkers for immunotherapy trials: A data driven approach by the CIMT Immunoguiding Program ("CIP")
Show more Session VI: Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement